Rasagiline - Second-Generation MAO-B Inhibitor for the Treatment of Parkinson's Disease
Key Data:
Drug (Brand / Generic)
Azilect / Rasagiline
Company/Licensee
Teva Pharmaceutical/Lundbeck
Therapy Class
MAO-B inhibitor
Product Description
Selective inhibitor of MAO-B, an enzyme that degrades dopamine
Current Indication
Parkinson's disease
Market Sector
CNS
Development Status
Approved Europe and the US
